Boehringer’s zongertinib receives Priority Review from U.S. FDA for the treatment of HER2 (ERBB2)-mutant advanced non-small cell lung cancer
Ridgefield, Conn., U.S., and Ingelheim, GermanyZongertinib would be the first orally administered, targeted therapy for previously treated ...
HER2+ Non-Small Cell Lung Cancer Market is Predicted to Grow at a CAGR of 13.2% During the Study Period (2020–2034) | DelveInsight
The treatment landscape for HER2-positive NSCLC is rapidly evolving as research continues to reveal the genetic drivers of these tumors. Emerging therapies like Pyrotinib (Jiangsu HengRui Medicine), ...
Managed Healthcare Executive2d
Cost-Effectiveness Study: Libtayo “More Favorable” Than Keytruda for First-Line Treatment of Advanced NSCLC
Study shows that Libtayo plus chemotherapy has lower cost and a larger effect on improving quality-adjusted life years than ...
Lung Cancer Research Foundation Announces Research Collaboration with Israel Cancer Research Fund
The Lung Cancer Research Foundation (LCRF) is pleased to announce its partnership with Israel Cancer Research Fund (ICRF) on ...
Healthline9d
How Does Lung Cancer Affect Appetite? 13 Tips to Combat Weight Loss
Many people with lung cancer develop anemia, especially after chemotherapy treatment. Anemia occurs when your red blood cell levels drop too low. In one 2021 study, about 32% of the people with ...
labiotech1d
T cell engagers: A promising, fast-growing field for cancer and autoimmune disease treatments
Explore how T cell engagers could transform cancer and autoimmune treatments through promising trials and key collaborations.
Targeted Oncology2d
Brahmer Considers First-Line Immunotherapy Options in Metastatic NSCLC
During a Case-Based Roundtable® event, Julie R. Brahmer, MD, MSC, reviewed the CheckMate 9LA, KEYNOTE-407, and POSEIDON ...
The American Journal of Managed Care1d
2 Immunotherapies Show Comparable Benefits in Extensive-Stage Small Cell Lung Cancer
When added to chemotherapy, researchers found no significant difference in overall or progression-free survival between PD-1 ...
‘It’s working!’ Columbus cancer center is first in Georgia to administer this new therapy
John B. Amos Cancer Center at Piedmont Columbus Regional ’s midtown medical complex is the first in Georgia to offer this ...
Pharmabiz1d
Innovent receives second fast track designation from US FDA for IBI363 in squamous non-small cell lung cancer
San Francisco, US Tuesday, February 18, 2025, 09:00 Hrs [IST] ...